UBS Group’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.66K | Sell |
136
-4,840
| -97% | -$198K | ﹤0.01% | 8757 |
|
|
2025
Q4 | $192K | Buy |
4,976
+4,853
| +3,946% | +$165K | ﹤0.01% | 6603 |
|
|
2025
Q3 | $3.36K | Sell |
123
-11,093
| -99% | -$253K | ﹤0.01% | 9052 |
|
|
2025
Q2 | $217K | Buy |
+11,216
| New | +$204K | ﹤0.01% | 6667 |
|
|
2025
Q1 | – | Sell |
-168
| Closed | -$4.02K | – | 10225 |
|
|
2024
Q4 | $4.02K | Buy |
+168
| New | +$4.64K | ﹤0.01% | 8799 |
|
|
2024
Q2 | – | Sell |
-698
| Closed | -$20.3K | – | 9513 |
|
|
2024
Q1 | $20.3K | Sell |
698
-751
| -52% | -$20.6K | ﹤0.01% | 6924 |
|
|
2023
Q4 | $35.4K | Sell |
1,449
-81
| -5% | -$1.6K | ﹤0.01% | 6746 |
|
|
2023
Q3 | $30K | Buy |
1,530
+1,036
| +210% | +$23K | ﹤0.01% | 6585 |
|
|
2023
Q2 | $11.8K | Buy |
+494
| New | +$11.9K | ﹤0.01% | 7091 |
|
|
2023
Q1 | – | Sell |
-3,290
| Closed | -$82.2K | – | 9597 |
|
|
2022
Q4 | $82.2K | Buy |
3,290
+2,313
| +237% | +$57.5K | ﹤0.01% | 6279 |
|
|
2022
Q3 | $24K | Buy |
977
+648
| +197% | +$16.5K | ﹤0.01% | 7133 |
|
|
2022
Q2 | $7K | Sell |
329
-1,355
| -80% | -$29.8K | ﹤0.01% | 8451 |
|
|
2022
Q1 | $47K | Sell |
1,684
-622
| -27% | -$18.4K | ﹤0.01% | 6555 |
|
|
2021
Q4 | $89K | Buy |
2,306
+2,182
| +1,760% | +$93.1K | ﹤0.01% | 6412 |
|
|
2021
Q3 | $6K | Sell |
124
-210
| -63% | -$9.81K | ﹤0.01% | 8408 |
|
|
2021
Q2 | $17K | Sell |
334
-2,419
| -88% | -$118K | ﹤0.01% | 7499 |
|
|
2021
Q1 | $141K | Buy |
+2,753
| New | +$150K | ﹤0.01% | 5700 |
|
|
2020
Q4 | – | Sell |
-701
| Closed | -$27K | – | 8374 |
|
|
2020
Q3 | $27K | Buy |
701
+615
| +715% | +$25.1K | ﹤0.01% | 6066 |
|
|
2020
Q2 | $4K | Sell |
86
-817
| -90% | -$31.3K | ﹤0.01% | 7433 |
|
|
2020
Q1 | $26K | Buy |
+903
| New | +$31.1K | ﹤0.01% | 6320 |
|
|
2019
Q4 | – | Sell |
-233
| Closed | -$6K | – | 8101 |
|
|
2019
Q3 | $6K | Sell |
233
-1,055
| -82% | -$28.7K | ﹤0.01% | 7393 |
|
|
2019
Q2 | $37K | Buy |
1,288
+1,205
| +1,452% | +$33.6K | ﹤0.01% | 6161 |
|
|
2019
Q1 | $2K | Sell |
83
-1,927
| -96% | -$50.5K | ﹤0.01% | 7419 |
|
|
2018
Q4 | $47K | Sell |
2,010
-922
| -31% | -$25.2K | ﹤0.01% | 6132 |
|
|
2018
Q3 | $101K | Buy |
2,932
+1,862
| +174% | +$62.8K | ﹤0.01% | 5590 |
|
|
2018
Q2 | $35K | Buy |
1,070
+251
| +31% | +$8.25K | ﹤0.01% | 6273 |
|
|
2018
Q1 | $27K | Buy |
819
+103
| +14% | +$3.36K | ﹤0.01% | 6173 |
|
|
2017
Q4 | $20K | Buy |
+716
| New | +$20.1K | ﹤0.01% | 6554 |
|
|
2017
Q3 | – | Sell |
-36
| Closed | -$1K | – | 7715 |
|
|
2017
Q2 | $1K | Sell |
36
-893
| -96% | -$20K | ﹤0.01% | 7475 |
|
|
2017
Q1 | $22K | Sell |
929
-983
| -51% | -$20.9K | ﹤0.01% | 6067 |
|
|
2016
Q4 | $35K | Buy |
+1,912
| New | +$38.1K | ﹤0.01% | 6108 |
|
|
2016
Q2 | – | Sell |
-458
| Closed | -$9K | – | 7718 |
|
|
2016
Q1 | $9K | Sell |
458
-1,405
| -75% | -$27.2K | ﹤0.01% | 6707 |
|
|
2015
Q4 | $54K | Buy |
1,863
+1,786
| +2,319% | +$51.6K | ﹤0.01% | 5744 |
|
|
2015
Q3 | $2K | Sell |
77
-781
| -91% | -$26.4K | ﹤0.01% | 8058 |
|
|
2015
Q2 | $31K | Buy |
858
+624
| +267% | +$21.5K | ﹤0.01% | 6440 |
|
|
2015
Q1 | $8K | Buy |
+234
| New | +$7.15K | ﹤0.01% | 7796 |
|
Other funds holding BBC
KCP
MCM
QCM
APW
FTUS
UBS Group's BBC Position: Q1 2026 in Review
UBS Group reduced its Virtus Biotech Clinical Trials ETF (BBC) stake by 97% in Q1 2026, selling an estimated $198K and leaving 136 shares worth $5.66K. The position accounts for ﹤0.01% of the portfolio, ranked #8757.
UBS Group first reported a position in BBC in Q1 2015 and has held it in 36 quarters since. The position peaked at $217K in Q2 2025. 20 funds tracked by Wall St. Rank hold BBC as of Q1 2026.
- UBS Group held 136 shares of Virtus Biotech Clinical Trials ETF worth $5.66K as of Q1 2026.
- UBS Group sold 4,840 Virtus Biotech Clinical Trials ETF shares in Q1 2026, an estimated $198K.
- Virtus Biotech Clinical Trials ETF made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8757 holding.
- UBS Group first reported a position in Virtus Biotech Clinical Trials ETF in Q1 2015 and has held it in 36 quarters since.
- UBS Group's Virtus Biotech Clinical Trials ETF position peaked at $217K in Q2 2025.
- 20 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.